×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [128]
内容类型
期刊论文 [126]
会议论文 [2]
发表日期
2022 [1]
2021 [8]
2020 [12]
2019 [5]
2018 [8]
2017 [17]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共128条,第1-10条
帮助
限定条件
专题:上海药物研究所
第一署名单位
第一作者单位
通讯作者单位
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
发表日期升序
发表日期降序
提交时间升序
提交时间降序
题名升序
题名降序
作者升序
作者降序
Multi-level fingerprinting and cardiomyocyte protection evaluation for comparing polysaccharides from six Panax herbal medicines
期刊论文
CARBOHYDRATE POLYMERS, 2022, 卷号: 277, 页码: 10
作者:
Liu, Jie
;
Wang, Hong-da
;
Yang, Fei-fei
;
Chen, Bo-xue
;
Li, Xue
收藏
  |  
浏览/下载:93/0
  |  
提交时间:2022/01/04
Panax
Polysaccharide
Oligosaccharide spectrum
Untargeted metabolomics
Cardiomyocyte protection
Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD-L1 Expression for Circumventing Immune Resistance of Cancer
期刊论文
ADVANCED MATERIALS, 2021, 页码: 12
作者:
Zhou, Fengqi
;
Gao, Jing
;
Tang, Yang
;
Zou, Zhifeng
;
Jiao, Shi
收藏
  |  
浏览/下载:36/0
  |  
提交时间:2021/11/04
antigen presentation
autophagy inhibition
immune resistance
immunotherapy
prodrug nanovesicles
Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9
作者:
Zhou, Yu-bo
;
Zhang, Yang-ming
;
Huang, Hong-hui
;
Shen, Li-jing
;
Han, Xiao-feng
收藏
  |  
浏览/下载:92/0
  |  
提交时间:2021/11/04
multiple myeloma
HDAC inhibitor
bisthianostat
pharmacodynamics
pharmacokinetics
phase 1a clinical trial
antitumor drug
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
期刊论文
ADVANCED MATERIALS, 2021, 页码: 37
作者:
Saeed, Madiha
;
Chen, Fangming
;
Ye, Jiayi
;
Shi, Yang
;
Lammers, Twan
收藏
  |  
浏览/下载:34/0
  |  
提交时间:2021/08/17
clinical translation
nanobiomaterials
nanovaccines
normalization cancer immunotherapy
primary and adaptive resistance
tumor immune microenvironment
Rescue of maternal immune activation-induced behavioral abnormalities in adult mouse offspring by pathogen-activated maternal T-reg cells
期刊论文
NATURE NEUROSCIENCE, 2021, 页码: 33
作者:
Xu, Zhipeng
;
Zhang, Xiaoyun
;
Chang, Hao
;
Kong, Yue
;
Ni, Yangyue
收藏
  |  
浏览/下载:84/0
  |  
提交时间:2021/05/24
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K delta inhibitor idelalisib
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 13
作者:
Zhou, Xiao-ru
;
Li, Xiao
;
Liao, Li-ping
;
Han, Jie
;
Huang, Jing
收藏
  |  
浏览/下载:28/0
  |  
提交时间:2021/06/11
mantle cell lymphoma
idelalisib
drug resistance
P300
CBP
synergistic drug action
PI3Kδ
epigenetics
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K delta inhibitor idelalisib
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 13
作者:
Zhou, Xiao-ru
;
Li, Xiao
;
Liao, Li-ping
;
Han, Jie
;
Huang, Jing
收藏
  |  
浏览/下载:25/0
  |  
提交时间:2021/06/11
mantle cell lymphoma
idelalisib
drug resistance
P300
CBP
synergistic drug action
PI3Kδ
epigenetics
Synthesis of 2-ethoxycarbonylthieno[2,3-b]quinolines in biomass-derived solvent gamma-valerolactone and their biological evaluation against protein tyrosine phosphatase 1B
期刊论文
RSC ADVANCES, 2021, 卷号: 11, 期号: 6, 页码: 3216-3220
作者:
Mu, Xu-Yang
;
Wang, Zhi-Jia
;
Feng, Bo
;
Xu, Lei
;
Gao, Li-Xin
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2021/05/24
Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors
期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 卷号: 209, 页码: 10
作者:
Xiang, Hao-Yue
;
Wang, Xiang
;
Chen, Yan-Hong
;
Zhang, Xi
;
Tan, Cun
收藏
  |  
浏览/下载:33/0
  |  
提交时间:2021/05/24
PI3K
Pyrrolo[2,1-f][1,2,4]triazine
Anti-cancer
Target therapy
Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy
期刊论文
ACTA PHARMACOLOGICA SINICA, 2020, 页码: 8
作者:
收藏
  |  
浏览/下载:31/0
  |  
提交时间:2021/05/24
tumor-targeted delivery
immunogenic cell death
PD-1
PD-L1 blockade
tumor immune microenvironment
irinotecan
JQ1
immune checkpoint
©版权所有 ©2017 CSpace - Powered by
CSpace